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Abstract
Background: Brucellosis is an endemic infection in Georgia. We conducted a review of patient records with a
suspected or confirmed diagnosis of brucellosis over three decades at the central referral hospital for brucellosis
cases, the Institute of Parasitology and Tropical Medicine (IPTM) in Tbilisi. The purpose was to describe the
demographic profile and clinical characteristics as well as diagnostic and treatment strategies in patients with
brucellosis.
Methods: Data were abstracted from randomly selected patient records at the IPTM. In total, 300 records were
reviewed from three time periods: 1970-73, 1988-89, and 2004-2008.
Results: The age distribution of patients shifted from a median age of 40 years in the first time period to 20 years
in the third time period. Azeri ethnicity was an increasing proportion of the total number of cases. The frequency
of relapsed infection was 14.7% (44 cases). A total of 50 patients received vaccine therapy, and although the
vaccine produced immune responses, demonstrated by an increase in agglutination titers, it was not associated
with improved outcome.
Conclusion: The demographics of brucellosis in Georgia fit a profile of persons that tend sheep. Osteoarticular
complications were commonly detected, especially in children. The changing pattern of brucellosis in Georgia
suggests clinicians should be updated about different trends in brucellosis in their country.
Background
Brucellosis is one of the most common zoonotic infec-
tions, with more than 500,000 new cases reported
annually worldwide [1]. The majority of cases occur in
the Mediterranean countries of Europe and Africa, Mid-
dle East, India, Central Asia, Mexico, and Central and
South America [2]. Before an etiology was determined,
brucellosis was known according to endemic geographi-
cal areas: Mediterranean fever, Gibraltar fever, Malta
fever, Cyprus fever, and Danube fever. Most experts
believe the number is only a small fraction of the overall
annual incidence [3]. Although the routes of transmis-
sion have been known for decades, and campaigns for
eradication have been attempted in many countries, the
consistently high number of cases reflects the challenges
associated with preventing the transmission of this
pathogen.
Brucellosis is caused by infection with Brucella species
bacteria. The organism is a pleomorphic, gram-negative,
non-spore-forming coccobacillus. They are facultative
intracellular pathogens, localized predominantly in
organs with numerous macrophages such as lung,
spleen, liver, bone marrow, and synovium. Presently,
there are six recognized species of Brucella,f o u ro f
which are pathogenic to humans: B melitensis, B, abor-
tus, B. suis, and B. canis [4].
Human infection can occur through consumption of
contaminated, unpasteurized animal products, direct
contact with infected animal parts, and through the
inhalation of infected aerosolized particles. Brucellosis is
an occupational disease in shepherds, abattoir workers,
veterinarians, dairy-industry professionals, and personnel
in microbiology laboratories [5,6]. Transmission of B. * Correspondence: t_akhvlediani@yahoo.com
1Clinical Research Unit, Technology Management Company, Tbilisi, Georgia
Full list of author information is available at the end of the article
Akhvlediani et al. BMC Infectious Diseases 2010, 10:346
http://www.biomedcentral.com/1471-2334/10/346
© 2010 Akhvlediani et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.melitensis from person-to-person has also been reported
in the literature [7-9].
Human brucellosis is a systemic infection that may
manifest with a myriad of non-specific symptoms (e.g.,
fever, sweats, malaise, anorexia, headache, back pain) as
well as substantial residual disability. The onset can be
insidious or acute, generally beginning within 2 to 4
weeks after inoculation. An “undulant” fever pattern is
apparent in patients who are untreated for long periods
of time [10]. Osteoarticular disease is the most common
complication, followed by the involvement of reproduc-
tive system. Endocarditis remains the principal cause of
mortality in the course of brucellosis [11]. Childhood
brucellosis generally exhibits a more benign course in
terms of the rate and severity of complications and the
response to treatment [12,13].
Brucellosis is an endemic infection in Georgia.
According to the data of the National Center of Disease
Control and Public Health of Georgia, 168 and 175
cases of brucellosis were reported in 2008 and 2009,
respectively. However, the real numbers can be higher
because not all the patients seek medical treatment and
even if they do, not all the cases are reported by the
physicians to the public health system. The brucellosis
is diagnosed based on the slide (Huddelson) and tube
(Right) agglutination tests. The treatment implies tradi-
tional three course treatment with antibiotics discussed
below. However, WHO recommended treatment is
becoming more popular among physicians. The first
case of brucellosis in Georgia, with serological and
microbiological confirmation, was described by Dr. N.
Makhviladze in 1923 [14]. In the following decades, bru-
cellosis was the subject of extensive observation. Most
suspected brucellosis patients in Georgia are referred to
the Institute of Parasitology and Tropical Medicine
(IPTM) in Tbilisi. It is estimated that the IPTM annually
tests about 400 clinical samples for serological evidence
of brucellosis, with approximately 150 positive tests
reported per year. The diagnosis of brucellosis in Geor-
gia has always been based on the slide and tube aggluti-
nation tests, and has not changed over three decades.
Health care has changed substantially in Georgia in
the last 40 years, due to advances in science and medi-
cine as well as social and political upheaval and reform.
In the period before the collapse of the Soviet Union,
subsidized medical care resulted in minimal costs for
patients, thereby encouraging utilization of medical ser-
vices. Currently many health services are becoming pri-
vatized, and health insurance is not widely available.
However, diagnostics and treatment for brucellosis
remain subsidized by the Georgian government at the
IPTM.
In the 1970s, vaccine therapy was administered either
in conjunction with antibiotics or as a separate
therapeutic option. Heat-inactivated Brucella polyvalent
vaccine was injected intravenously to activate the
immune system, which was regarded as a curative reac-
tion [15]. Vaccine therapy was mainly indicated for
chronic brucellosis. However, it was occasionally used in
acute cases, at the discretion of the treating physician
[16].
Examination of the epidemiology and clinical charac-
teristics of this infection was not systemically conducted
in the recent past in Georgia. It is important that health
care providers and public health leaders are aware of
current trends in brucellosis, because the scenarios in
which brucellosis is acquired, as well as the types of
patients exposed and duration of infection before pre-
sentation, are influenced by multiple factors and may
change over time. Assumptionsa b o u tb r u c e l l o s i sf r o m
10-20 years ago may be incorrect, leading to inaccurate
clinical suspicion of infection and inappropriately tar-
geted public health surveillance efforts.
To address the lack of recent data on human brucello-
sis in the region and explore changes in the epidemiol-
ogy and clinical presentation and course over time, we
conducted a medical chart review of suspected or con-
firmed brucellosis patients at the IPTM in Tbilisi. The
p u r p o s eo ft h es t u d yw a st ob e t t e ru n d e r s t a n dt h e
demographic distribution as well as clinical manifesta-
tions and the patterns of response to treatment of the
disease. The review allowed for comparisons in manage-
ment strategies over three decades.
Methods
Data were abstracted from randomly selected inpatient
records of suspected or confirmed brucellosis patients at
the IPTM. Before initiation, this study was reviewed by
the Institutional Review Board (IRB) and it was deter-
mined not to constitute the research involving human
subject. An exemption certificate attesting this fact was
issued by the IRB.
In total, 300 records were reviewed from three time
periods: 1970-73, 1988-89, and 2004-2008. Patients who
were initially suspected to have brucellosis but were
then given an alternate final diagnosis were excluded
from most analyses. The first time period was chosen to
characterize a period where vaccine therapy was still
used; the second is a period before the collapse of the
Soviet Union, when subsidized medical care resulted in
minimal costs for patients, thereby encouraging utiliza-
tion of medical services. The most recent time period
was selected to evaluate the current situation of referral
patterns for brucellosis. The charts were reviewed by a
single investigator which ensured uniformity in the data
recording. Information collected included demographic
information, risk factors for potential exposure to bru-
cellosis, clinical manifestations, diagnostic laboratory
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of relapsed infection was also recorded.
Demographic, epidemiologic, and clinical parameters
were assessed using chi-squared and Fisher exact tests.
A p-value less than 0.05 was considered significant.
Logistic regression was used to further evaluate associa-
tions detected in bivariate analysis. All analyses were
conducted using Epi Info™Version 3.4 (Centers for Dis-
ease Control and Prevention, Atlanta, GA).
Results
Epidemiologic changes over time
Most brucellosis patients (87.6%) were from eastern
Georgia, with the most common regions for brucellosis
cases being the Kvemo Kartli and Kakheti regions
(figure 1). Traditionally, animal exposures, especially
sheep husbandry, were more prevalent in eastern
Georgia. In the first time period, there were more cases in
Kvemo Kartli region, while Kakheti predominated in the
second and third time points. Shepherd (29%) was the
most common occupation followed by farmer (12.3%).
Azeri ethnicity was an increasing proportion in the
total number of cases. By the most recent time, 62% of
the patients were Azeris (Table 1), which represent only
6.5% of the Georgian population. The prevalence of bru-
cellosis was much higher in men (85%). The age distri-
bution of patients shifted from a median age of 40 years
in the first time period to 20 years in the third time per-
iod. There were 11 children less than 10 years with bru-
cellosis (9 of them in the third time period) and 54
between 10 and 20 years (39 in the third time period).
An accurate description of potential risk factors for
developing brucellosis was not available in some of the
medical charts. In cases of relapsed or latent brucellosis,
the epidemiological information was not provided,
assuming that it was collected when the patient pre-
sented with acute infection. A large majority (86.3%) of
patients had contact with animals before symptom devel-
opment. In 12.7%, animal contact was the only type of
exposure. A total of 40.4% of patient records noted con-
tact with sheep, 35.0% had contact with both sheep and
cattle. Consumption of unpasteurized products was
Figure 1 Frequency of Brucellosis Cases in Regions of Georgia.
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exposure solely with animal products (Table 2). One
patient had an exposure to a live attenuated vaccine dur-
ing animal vaccination.
Diagnosis of brucellosis
The core criteria used to diagnose patients with brucel-
losis did not change over time. In all three time periods,
diagnosis of brucellosis was based on the Wright and
Huddelson agglutination tests, in combination with clini-
cal and epidemiological information. All patients were
tested at least once for agglutinating antibodies, and 50%
of patients were tested twice. The tube agglutination titer
of 1:200 and higher was considered positive for brucello-
sis. Cultures of blood or other tissue samples were not
routinely performed in any time period. An additional
diagnostic test practiced mostly in the first time period is
an allergy skin test. The Burnè skin test was conducted
using Melitin (culture filtrate, toxin in broth). In total, 66
patients were tested with the Burnè skin test (64 in the
first and 2 in the second time period) and 44 were posi-
tive. This test is no longer used because of the high rate
of side effects, particularly severe allergic reactions
[14,17]. The laboratory analyses consistently included
complete blood count (CBC), urinalysis, C-reactive pro-
tein (CRP), erythrocyte sedimentation rate (ESR), and
blood glucose.
Patients were categorized as brucellosis primaria (pri-
mary or acute brucellosis), brucellosis latenta (subacute
course of infection), brucellosis recidiva (relapsed bru-
cellosis), and status post-brucellosis (residual/chronic
disease). Criteria for categorization are somewhat arbi-
trary, which is consistent with observations for other
publications [11]. The final diagnosis was brucellosis in
91.6% of charts. Primary brucellosis was the diagnosis in
52.5% of presenting patients. Alternative diagnoses
included polyarthritis (30.8%) and chronic cholecystitis
(26.9%).
Clinical Characteristics
Patients with a final diagnosis of brucellosis were 2.9
times more likely to have documented fever on admis-
sion than non-brucellosis patients (p = 0.02). No other
symptoms were significantly different between brucello-
sis and non-brucellosis patients. The remaining analyses
pertain only to patients with a final diagnosis of brucel-
losis. Fever, arthralgias, and sweats were the most fre-
quently recorded symptoms for acute brucellosis
patients (Table 3). Among relapse, latent, and chronic
brucellosis patients, arthralgia was the most frequently
noted symptom. Neuropsychiatric symptoms such as
depression, difficulty concentrating and sleep distur-
bance, were observed rarely. The clinical symptoms did
not differ over time.
Pediatric records were significantly more likely to note
fever on admission (OR = 3.7, p = 0.02) and less likely
to report aches (OR = 0.16, p = 0.0004). The maximum
temperature recorded was significantly higher in chil-
dren (38.6°C versus 38.2°C, p = 0.02) controlling for the
classification of brucellosis (i.e., acute, relapse, latent, or
chronic). Pediatric records were also 2.8 times more
likely to note arthritis controlling for decade and classi-
fication of brucellosis (p = 0.05) (Table 4).
Forty-eight patients presented with complicated dis-
ease, including osteoarticular complications (32), orchitis
(15), and hepatitis (1). There were significantly more
Table 1 Demographic Characteristics of Brucellosis
Patients by Decade
Demographic Group Decade 1 Decade 2 Decade 3
Gender
Male 66 (77.6%) 79 (88.8%) 89 (89%)
Female 19 (22.4%) 10 (11.2%) 11 (11%)
Age Group
1-9 2 (2.4%) 0 9 (9.1%)
10-19 4 (4.8%) 11 (12.5%) 39 (39.4%)
20-29 17 (20.2%) 32 (36.4%) 23 (23.2%)
30-39 23 (27.4%) 15 (17%) 14 (14.1%)
40-49 18 (21.4%) 4 (4.5%) 6 (6.1%)
50-59 14 (16.7%) 21 (23.9%) 6 (6.1%)
≥60 6 (7%) 5 (5.7%) 2 (2.0%)
Nationality
Georgian 37 (43.5%) 48 (53.9%) 36 (36%)
Azerbaijani 19 (22.4%) 33 (37.1%) 62 (62%)
Armenian 14 (16.5%) 5 (5.6%) 0
Other 15 (17.6%) 3 (3.4%) 2 (2%)
Occupation
Farmer 10 (11.8%) 10 (11.2%) 12 (12%)
Shepherd 19 (22.4%) 31 (34.8%) 30 (30%)
Housewife 7 (8.2%) 6 (6.7%) 7 (7%)
Student 2 (2.4%) 5 (5.6%) 12 (12%)
Retired 7 (8.2%) 4 (4.5%) 1 (1%)
Other 40 (47.1%) 33 (37.1%) 38 (38%)
Total 85 89 100
Table 2 Exposure Types in Patients with Brucellosis
Exposure Frequency Percent
Contact with animal 27 12.7%
Contact with animal product 35 16.5%
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complicated cases in the first decade, as compared to 15
and 27 in the second and third time periods, respec-
tively (p = 0.004). People with complications did not
have rising agglutination titers, and did not have a
higher initial titer on average. There were 44 brucellosis
patients with relapsed infection (16%), with the majority
of relapse cases recorded in the first time period (31
cases) compared to the second third time periods (five
and eight cases, respectively, p < 0.0001). Relapse patient
records were 2.7 times more likely to report aches (p =
0.004) and 2.8 times more likely to note lymphadenopa-
thy (p = 0.04).
Only 2.7% of patients had anemia. Leukocytosis was
detected in 7.4% with 69.6% of patients with lymphocy-
tosis. An additional 12.5% had leucopaenia. Only
approximately half (64.6%) of the brucellosis patients
reviewed had an elevated ESR. Interestingly, only 1.21%
of chronic brucellosis cases had elevated ESR. There was
no association between ESR and complications. Rising
agglutination titer was not associated with rising leuko-
cyte count, while increasing titer correlated with
increasing ESR (p = 0.01) (figure 2). On the other hand,
change in ESR was not associated with fever, compli-
cated disease or vaccine therapy.
Routine antibiotic treatment at IPTM was three
courses of different antibiotics with 10 days of treatment
interruption between each course. The typical regimen
was to start with tetracycline, continue with chloram-
phenicol, followed by doxycycline. The long term
administration of antibiotics was generally avoided
because it was regarded as harmful and possibly leading
to the development of fungal infections, specifically can-
didiasis. A total of 19.1% of patients received antibiotic
treatment before admitting to the IPTM. The most
commonly used antibiotic was chloramphenicol.
Vaccine therapy
Vaccine therapy was applied to 50 patients (17.1%), pri-
marily in the first time period (1970-73). The majority
of patients that received vaccine therapy were those

























Rigors 20 (12.8) 6 (13.6) 5 (8.1) 1 (10.0) 32 (11.8)




Fatigue 63 (40.1) 9 (20.5) 16
(25.8)
1 (10.0) 89 (32.6)
Aches 28 (18.2) 17 (40.5) 20
(32.3)







Arthritis 20 (12.7) 5 (11.4) 7 (11.3) 1 (10.0) 33 (12.1)
Myalgia 17 (10.8) 5 (11.4) 3 (4.8) 1 (10.0) 26 (9.5)
Bursitis 1 (0.6) 0 4 (6.5) 0 5 (1.8)
Anorexia 10 (6.4) 2 (4.5) 1 (1.6) 0 13 (4.8)
Abdominal Pain 8 (5.1) 3 (6.8) 5 (8.1) 1 (10.0) 17 (6.3)
Hepatomegaly 38 (24.2) 15 (34.1) 14
(22.6)
2 (20.0) 69 (25.3)
Splenomegaly 14 (8.9) 5 (11.4) 2 (3.2) 0 21 (7.7)
Lymphadenopathy 15 (9.6) 7 (15.9) 4 (6.5) 0 26 (9.5)
Cough 4 (2.5) 1 (2.3) 4 (6.5) 0 9 (3.3)
Testicular Pain** 12 (9.0) 4 (10.0) 0 0 16 (6.8)
Testicular
swelling**
14 (10.5) 3 (7.5) 0 0 17 (7.3)
Total 157 44 63 10 274
*The following symptoms were assessed in the medical charts, but were
recorded in fewer than five charts and are therefore not listed in the table
above: weight loss, diarrhea, constipation, jaundice, sore throat, tonsillitis,
pneumonia, depression, difficulty concentrating, skin lesions, and ocular
symptoms.
**Percentages reflect only male patients
Table 4 Comparison of the clinical presentations of acute







Fever 30 (88.2) 98 (81.0) 128 (82.6)
Sweats 27 (79.4) 83 (68.6) 110 (71.0)
Rigors 5 (14.7) 15 (12.5) 20 (13.0)
Malaise 20 (58.8) 59 (48.8) 79 (51.0)
Fatigue 17 (50.0) 46 (38.0) 63 (40.6)
Aches 2 (5.9) 25 (21.2) 27 (17.8)
Arthralgia 32 (91.1) 104 (86.0) 136 (87.7)
Arthritis 10 (29.4) 9 (7.4) 19 (12.3)
Myalgia 2 (5.9) 15 (12.4) 17 (11.0)
Bursitis 0 1 (0.8) 1 (0.6)
Anorexia 4 (11.8) 6 (5.0) 10 (6.5)
Abdominal Pain 0 8 (6.7) 8 (5.2)
Hepatomegaly 10 (29.4) 27 (22.3) 37 (23.9)
Splenomegaly 5 (14.7) 9 (7.4) 14 (9.0)
Lymphadenopathy 8 (23.5) 7 (5.8) 15 (9.7)
Cough 1 (2.9) 3 (2.5) 4 (2.6)
Testicular Pain** 1 (2.9) 11 (9.1) 12 (7.7)
Testicular swelling** 1 (2.9) 13 (10.7) 14 (9.0)
Total 34 121 155
*The following symptoms were assessed in the medical charts, but were
recorded in fewer than five charts and are therefore not listed in the table
above: bursitis, weight loss, diarrhea, constipation, jaundice, sore throat,
tonsillitis, pneumonia, depression, difficulty concentrating, skin lesions, and
ocular symptoms.
**Percentages reflect only male patients
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patients). A greater proportion of relapse patients
received vaccine therapy (15/44, 34%) than those with a
final diagnosis of acute (26/157, 16.6%), latent (9/63,
14.3%), or status post-brucellosis (0/10). Most of the
patients with relapse were treated by the vaccine and no
antibiotics. One course of vaccine therapy typically
included 15 injections. Each administration of vaccine
typically induced a temperature reaction of more than
38°C. In 22.9% of patients receiving vaccine therapy, the
treatment was discontinued due to side effects, which
included nausea, vomiting, temperature >40°C, and
hematuria. An additional 8.3% of patients receiving vac-
cine therapy requested that the treatment cease.
The vaccine treatment group were 4.3 times as likely
(p = 0.031) to have a rising agglutination titer between
the first and second blood draws (vaccination occurred
between the two blood draws). This association
remained when adjusting for age and decade.
The average change in titer for patients that received
vaccine therapy was twofold, whereas on average, non-
vaccinated patients did not demonstrate an increase in
agglutination titer between the first and second blood
draw (figure 3).
Conclusions
Brucellosis continues to have a substantial impact on
public health in many countries of the world, with parti-
cular importance in Georgia. To increase the under-
standing of this complex infection and improve
worldwide control, it is useful to review the past experi-
ence of different countries as well as examine trends in
epidemiology and clinical manifestations over time
[18,19]. At the IPTM, a number of interesting trends
were observed, including substantial shifts in the demo-
graphics of brucellosis cases, clinical differences between
adult and pediatric cases, interesting patterns of initial
clinical symptoms and laboratory findings, and a
Figure 2 Correlation of erythrocyte sedimentation rate (ESR) with agglutination titer in patients with brucellosis (p = 0.01).
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The possible explanations for these trends are discussed
below. Additionally, vaccine therapy was documented to
have an immunogenic response, evidenced by rising
agglutination titers, without a therapeutic effect.
Azeri ethnicity comprised an increasing proportion of
cases over time. In the third time period, cases of bru-
cellosis in Azeris were twice as much as cases in ethnic
Georgians. There are many possible explanations for
this observation. One possible contributing factor is that
the Azeri population in Georgia has increased from
5.1% in 1979 to 6.5% according to the last census in
2002 [20]. Another possible explanation is that Azeris in
Georgia tend to be employed at occupations at high-risk
for brucellosis, such as sheep herding. Health care utili-
zation may also explain these observations, as Azeri
patients may be more prone to stay in the hospital,
while Georgians prefer out-patient treatment, in which
case, medical charts are not maintained. The predomi-
nance of males over females may be a result of activities
that males primarily perform that lead to exposure to
the infection: working as shepherds, slaughtering and
skinning animals, processing animal hides, etc. There
was also an observed trend of more cases in children in
the recent period. This observation may be related to
increasing involvement of children in the farm activities,
because of economic constraints in the country. Some-
times, children are taken to the pastures as the families
follow their sheep herds.
Some of the interesting aspects of the clinical observa-
t i o n sf r o mt h i sr e v i e wa r ew o r t hm e n t i o n i n g .T h eh i g h
percentage of children with osteoarticular complications
is a finding to emphasize to practitioners in the region,
and to alert pediatric specialists in endemic areas. Prior
studies have described osteoarticular findings in children
[12,21]. In our survey, children were more likely to have
these complications, thus providing data to the medical
community of the need for vigilance for these findings
in children. Another prior observation in children is the
frequency of cytopenias, including pancytopenia, asso-
ciated with brucellosis [22]. We observed a low rate of
anemia (2.7%), but a significant percentage of patients
Figure 3 Impact of vaccine therapy on agglutination titer by decade (p = 0.031).
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percentages of pancytopenia described in the previous
report was attributable to a higher number of pediatric
patients in that study. Our study adds further evidence
to the observation that leucopenia can be associated
with brucellosis.
Only approximately half of the brucellosis patients had
an elevated erythrocyte sedimentation rate. This obser-
vation is surprising in the setting of an infection that
should produce inflammation. However, it has been
reported that chronic brucellosis patients may not have
fever present [14,16], suggesting an adaptive response to
the chronic presence of Brucella organisms in the body.
This observation may suggest that the ability of Brucella
species to evade the immune system occurs in patients,
especially with chronic infection, thus leading to a dis-
proportionately low level of inflammation. Prospective
studies should investigate the pattern of inflammatory
markers in brucellosis patient over time, thus providing
further insight into the interaction between the patho-
gen and the immune system.
Neuropsychiatric symptoms were rarely reported in
the documentation of the initial presentation of brucel-
losis, even though many patients had a prolonged dura-
tion of infection on presentation. Brucellosis has been
documented to cause neuropsychiatric symptoms,
although the true incidence of these symptoms asso-
ciated with active infection is unknown, but likely
underreported. It is likely that the brucellosis patients
studied were not evaluated for these symptoms, due to
the low clinical awareness of the potential neurophy-
chiatric impact of brucellosis [23]. This practice still
occurs in Georgia and physicians in other countries may
follow a similar practice pattern. It is also interesting
that this finding did not change over the three decades
of observation. Prospective assessment of neuropsychia-
tric findings with brucellosis is needed, and these find-
ings could be utilized in campaigns to educate
physicians on this effect of infection.
The proportion of patient records with documented
complications increased over time, especially osteoarti-
cular complications. This trend possibly reflects the
improved clinical recognition and diagnosis of complica-
tions, rather than a real increase in complications. Alter-
natively, this trend may indicate changing patterns of
access to medical care. The actual cause of complica-
tions with brucellosis is unknown, but host susceptibility
factors, bacterial strain, route of exposure, and delayed
treatment may all contribute. The duration of infection
before treatment may have changed over time, as
decreasing access to health care may have led to
increased rates of complications. Neither the agglutina-
tion titer nor the ESR was elevated in complicated dis-
ease, leading to the conclusion that these tests were not
helpful in predicting complicated infections. These
observations indicate that clinicians in referral centers
similar to IPTM should carefully evaluate all potential
brucellosis cases for the complications described in this
study.
The occurrence of relapsed brucellosis infection after
initial treatment was most common during 1970-1973,
which was also the period of widespread use of exclusive
vaccine therapy. It is also possible that in recent years,
patients with relapse more often chose out-patient treat-
ment. Therefore, relapsed cases would not be observed
as frequently in the inpatient population, from which
the chart review was conducted.
Vaccine therapy is a treatment method that was used
exclusively in countries of the former Soviet Union.
Soviet scientists tried different routes of vaccine admin-
istration: subcutaneous, intradermal, intramuscular, and
intravenous [24]. In Georgia, intravenous use of vaccine
was practiced [14]. In our study, the vaccine therapy
was related to the increased agglutination titer, which
means the activation of humoral immunity. Presently,
vaccine therapy is not utilized because of its ineffective-
ness, discomfort, and adverse events to the patient, as
well as antibiotics being a more effective treatment
option.
The limitations of the study were primarily associated
with challenges inherent to retrospective review of clini-
cal and epidemiologic information. First, our analysis
does not fully reflect the actual morbidity with brucello-
sis in Georgia, as not all brucellosis cases in the country
are referred to IPTM. Also, a referral bias could affect
our conclusions as only physicians from certain regions
or only certain types of patients would be referred to
IPTM. Second, we could only review hospitalized cases
where charts are available. There is no documentation
for outpatient cases except for the registration log. Utili-
zation of inpatient cases may introduce a bias in favor
of more difficult or complicated cases, which would
explain the high rate of complications detected in the
more recent time periods. The most recent time period
may be susceptible to bias, in which cost of hospitaliza-
tion may be difficult for patients to pay, thereby select-
ing a unique population. As mentioned above, charts
were occasionally missing epidemiological information.
Additionally, out of the three courses of the antibiotic
treatment, only the first treatment course was recorded
from the inpatient record, as subsequent treatments
were recorded in outpatient records. The limited diag-
nostic capacity in earlier decades may have prevented
the accurate detection of complications.
The presented chart review provides substantial initial
information that public health and medical personnel
can utilize to improve health in Georgia. Education
campaigns about brucellosis to health care providers in
Akhvlediani et al. BMC Infectious Diseases 2010, 10:346
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Page 8 of 9Georgia can lead to better recognition of the clinical and
laboratory manifestations and complications of infection.
Pediatricians, in particular, may benefit from discussions
of the contrasting presentations of brucellosis between
adults and children; namely, higher temperature on pre-
sentation and more common osteoarticular complica-
tions. Further epidemiologic investigation will be
recommended for populations that referred high num-
bers of cases. This review provides a baseline measure-
ment for comparison as further changes in health care
and management of brucellosis occur in Georgia.
Finally, reviewing the experience of vaccine therapy pro-
vides useful information for the Brucella vaccine devel-
opment, providing documentation of immunogenic
effects but ineffectiveness as a therapy. Our data suggest
human Brucella vaccine candidates need to utilize corre-
lates of protection that are based on the cell-mediated
immune response, as the vaccine caused an increase in
serological measurements, but was observed to be
ineffective.
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